Trial Profile
Hippocampal Sparing and Limbic Predominant Tau Subtypes of Alzheimer's Disease Determined in Vivo Using [18F]-AV-1451 PET Imaging
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2015
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals; Eli Lilly and Company
- 21 Oct 2015 New trial record